Clinical Trial Update: A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

View source ↗

Summary

Takeda reports a database survey to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Immune Globulin Subcutaneous (Human), 20% Solution (immune globulin subcutaneous (human), 20% solution)

Snippet

Sponsor: Takeda | Conditions: Primary Immunodeficiency Diseases (PID) | Status: RECRUITING